Kloepfel MagazinKloepfel Magazin
    Top Article

    Charity Workshop: “Presenting with Confidence and Poise”

    19. May 2025

    Packaging Cost Optimization at a Branded Food Manufacturer

    19. May 2025

    NRW.BANK.Invest Zukunft: Your Competitive Edge for Tomorrow – Funding Available from May 19

    19. May 2025
    Facebook Twitter Instagram
    • Kloepfel Group
    • Kloepfel Consulting
    • Kloepfel Karriere
    LinkedIn Twitter Facebook Instagram YouTube
    Kloepfel MagazinKloepfel Magazin
    • START
    • NEWS
      • HWWI
      • INTERVIEWS
      • CAREER
      • KLOEPFEL GROUP
      • WHITEPAPER
      • WORK@KLOEPFEL
      • SURVEY
      • INDUSTRY NEWS
        • ENGINEERING
        • LOGISTICS
        • SUPPLY CHAIN
    • NEWSLETTER
    • CONTACT
      • IMPRINT
      • PRIVACY POLICY
    Kloepfel MagazinKloepfel Magazin
    Home»Industry News»Supply Chain»Pharmaceutical supply chains: EU advises on production sites in Europe
    Supply Chain

    Pharmaceutical supply chains: EU advises on production sites in Europe

    By Kloepfel1. May 2020Updated:19. May 20202 Mins Read
    LinkedIn Facebook WhatsApp Email
    Share
    LinkedIn Facebook Twitter WhatsApp Email

    Corona-Crisis inhibits supply from Asia

    EU health ministers held a video conference on Tuesday to discuss how to ensure the European supply of medicines. The reason for this was delivery shortfalls and delays of active ingredients and preparations from Asia.

    Cause for shortages often abroad

    An interview with Stefan Kluge in the ARD magazine “Plusminus” shows how serious the situation is. The director of intensive care medicine at the University Medical Center Hamburg said last week: “There are already hospitals in Germany that no longer have Propofol. Without Propofol, patients cannot be put under anesthesia – it is necessary, for example, for the ventilation of Covid-19 infected patients. The shortage is not only caused by increased demand: Problems at foreign production sites or long and confusing supply chains are frequent causes.

    Reduction of dependence on China and Co.

    Now the EU wants to reduce its dependence on production from foreign countries. Experience from the current pandemic would show that joint political efforts to expand pharmaceutical production at national level need to be stepped up to ensure independent and crisis-proof supply to the European population. All stakeholders (public authorities, NGOs, industry, marketing authorisation holders, wholesalers, pharmacies) should be involved at national and European level to take countermeasures.

    80 percent of all active ingredients from third countries

    This will be a non-inconsiderable challenge: 80 percent of all active ingredients in European medicines are sourced from third countries such as India, China and Taiwan. The reason for this is often the lower patent protection in these countries, so that generics can be produced and marketed in Europe before the patents expire in the EU area. Accordingly, production has been greatly expanded, and many preliminary stages are no longer produced in Europe. These are structures that have grown globally over decades.

    Source: www.kloepfel-consulting.com

    Share. LinkedIn Facebook Twitter WhatsApp Email

    Related Posts

    Mittelstand: Competitive Advantages Through Sustainability and Digitalization

    19. February 2025

    Henkel Divests American Business Units

    19. February 2025

    Bosch Reports Sharp Profit Decline

    19. February 2025

    Adidas Equips Mercedes Formula 1 Team

    20. January 2025

    Emirates SkyCargo Intensifies Freight Flights to Copenhagen

    20. January 2025

    CES 2025

    20. January 2025

    Comments are closed.

    Top Artikel

    Charity Workshop: “Presenting with Confidence and Poise”

    By Kloepfel19. May 2025

    An Interview with Delia Dittrich on Her Charity Workshop in Support of the Cancer Society…

    Packaging Cost Optimization at a Branded Food Manufacturer

    19. May 2025

    NRW.BANK.Invest Zukunft: Your Competitive Edge for Tomorrow – Funding Available from May 19

    19. May 2025

    Negotiation Training for Buyers

    19. May 2025

    Maker Stories: Interview with Frank Wischnewski

    19. May 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About us
    About us

    Das Magazin für den effektiveren Einkauf!

    Kloepfel Consulting GmbH
    Cecilienallee 6-7
    40474 Düsseldorf

    Telefon: +49 211 941 984 33
    E-Mail: info@kloepfel-consulting.com

    New Article

    Charity Workshop: “Presenting with Confidence and Poise”

    19. May 2025

    Packaging Cost Optimization at a Branded Food Manufacturer

    19. May 2025

    NRW.BANK.Invest Zukunft: Your Competitive Edge for Tomorrow – Funding Available from May 19

    19. May 2025
    © 2025 Kloepfel Consulting GmbH | All rights reserved
    • Home
    • News
    • Contact
    • Imprint
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.